These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33301862)

  • 1. Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals.
    Lee DY; Im E; Yoon D; Lee YS; Kim GS; Kim D; Kim SH
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1033-1057. PubMed ID: 33301862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy.
    Zhang Q; Yang C; Gao X; Dong J; Zhong C
    Phytother Res; 2024 Feb; 38(2):776-796. PubMed ID: 38050789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy.
    Lee J; Han Y; Wang W; Jo H; Kim H; Kim S; Yang KM; Kim SJ; Dhanasekaran DN; Song YS
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer natural products targeting immune checkpoint protein network.
    Chun KS; Kim DH; Raut PK; Surh YJ
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro.
    Guo Q; Malloy MW; Roweth HG; McAllister SS; Italiano JE; Battinelli EM
    Blood Adv; 2022 Oct; 6(20):5668-5675. PubMed ID: 35482455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular vesicle-based checkpoint regulation and immune state in cancer.
    Mortezaee K; Majidpoor J
    Med Oncol; 2022 Sep; 39(12):225. PubMed ID: 36175741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Impact of Phytochemicals on Immune Checkpoints: Implications for Cancer Immunotherapy.
    Power Coombs MR; Hoskin DW
    Methods Mol Biol; 2020; 2111():161-173. PubMed ID: 31933207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression.
    Filippone A; Lanza M; Mannino D; Raciti G; Colarossi C; Sciacca D; Cuzzocrea S; Paterniti I
    Cancer Immunol Immunother; 2022 Sep; 71(9):2067-2075. PubMed ID: 35092481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Traditional Chinese Medicine in Cancer Immunotherapy: Current Status and Future Directions.
    Xie J; Huang H; Li X; Ouyang L; Wang L; Liu D; Wei X; Tan P; Tu P; Hu Z
    Am J Chin Med; 2023; 51(7):1627-1651. PubMed ID: 37638827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
    Yan Y; Zhang L; Zuo Y; Qian H; Liu C
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy.
    Khatoon E; Parama D; Kumar A; Alqahtani MS; Abbas M; Girisa S; Sethi G; Kunnumakkara AB
    Life Sci; 2022 Oct; 306():120827. PubMed ID: 35907493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.
    Ghebeh H; Barhoush E; Tulbah A; Elkum N; Al-Tweigeri T; Dermime S
    BMC Cancer; 2008 Feb; 8():57. PubMed ID: 18294387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.